Innovation in healthcare: opportunity + capability

Inbio ventures

Latest news

Pharmstandard International S.A. Represented by Inbio Ventures Leads a $20M Syndicated Series C Financing in Avelas Biosciences

read more →

Our Portfolio Company, Protagonist Therapeutics, has successfully completed Initial Public Offering

read more →

Our Portfolio Company, Jounce Therapeutics, Signed a Major Collaboration Deal with Celgene to Develop Next-Generation Immuno-oncology Therapies

read more →